Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Vaccine|September 10, 2019
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adultsAllison Thompson, Erik Lamberth, Joseph Severs, et al.
Vaccine|November 29, 2021
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccinationKevin Cannon, Charles Elder, Mariano Young, et al.
Human Vaccines & Immunotherapeutics|January 8, 2026
Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trialBalachandra Giriappa, Nirmalkumar Choraria, Philip Ponce, et al.
Vaccine|July 28, 2021
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of ageNicola P Klein, Paula Peyrani, Kari Yacisin, et al.
The Pediatric Infectious Disease Journal|March 8, 2024
Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and ToddlersPiotr Korbal, Jacek Wysocki, Teresa Jackowska, et al.
Pediatrics|October 4, 2024
Safety of a 4-Dose 20-Valent Pneumococcal Conjugate Vaccine Series in Infants: A Randomized TrialGabriella Hajdu, Teena Hughes, G Laïssa Ouedraogo, et al.
Vaccine|May 27, 2023
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years oldDavid Fitz-Patrick, Mariano Young, Kari Yacisin, et al.
Human Vaccines & Immunotherapeutics|March 4, 2021
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of ageBrandon Essink, James Peterson, Kari Yacisin, et al.
The Pediatric Infectious Disease Journal|March 19, 2024
A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of AgeJay Meyer, Peter Silas, G Laïssa Ouedraogo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 28, 2020
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeDonald Hurley, Carl Griffin, Mariano Young, et al.
Pageof 6